U003 Combining Systemic Therapies: Should You Do It?
DESCRIPTION
With the expansion of our treatment armamentaria in dermatology we have many tools in our toolbox to manage treatment failure and patients with multiple dermatologic conditions. Practicing dermatologists are now getting introduced to all these new therapies including JAK inhibitors and emerging biologics. The use of these new agents in combination with each other or with more traditional immunomodulators are not well established. This session is targeted to familiarize practicing dermatologists on how to combine these medications in our daily practice and how to assess their safety profile in this setting.
LEARNING OBJECTIVES
Select the appropriate biologic and immunomodulator combinations in the real world.
Manage treatment failure with combination therapy.
Assess the safety profile of combining multiple agents.
SCHEDULE
7:30 AM
Introduction
Carole Bitar, MD, FAAD
7:35 AM
Combination Systemic Therapies in Connective Tissue Diseases
Carole Bitar, MD, FAAD
7:47 AM
Combination Systemic Therapies in Psoriasis
Erin E. Boh, MD, PhD, FAAD
7:59 AM
Combination systemic therapies in Hidradenitis Suppurativa
Andrea Tesvich Murina, MD, FAAD
8:11 AM
Combination Systemic therapies in Bullous Diseases
8:23 AM
Q&A session
DIRECTOR
Carole Bitar, MD, FAAD
SPEAKERS
Erin E. Boh, MD, PhD, FAAD
Katherine Brag, MD, FAAD
Andrea Tesvich Murina, MD, FAAD
Tulane University School of Medicine
DISCLOSURES
Carole Bitar, MD, FAAD
Arcutis Biotherapeutics – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Erin E. Boh, MD, PhD, FAAD
AbbVie – Investigator(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Bristol Myers Squibb – Investigator(Grants/Research Funding); CorEvitas – Investigator(Grants/Research Funding); Janssen-Ortho Inc. – Investigator(Grants/Research Funding), Speaker(Honoraria); Sanofi – Investigator(Grants/Research Funding);
Katherine Brag, MD, FAAD
No financial relationships exist with ineligible companies.
Andrea Tesvich Murina, MD, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Amgen – Speaker(Honoraria); Botanix Pharmaceuticals – Speaker(Honoraria); Galderma – Speaker(Honoraria); Janssen Biotech – Speaker(Honoraria); Leo Pharma – Advisory Board(Honoraria); Novartis – Speaker/Faculty Education(Honoraria); Ortho Dermatologics – Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); UCB Pharma – Speaker(Honoraria); VeraDermics Inc. – Advisory Board(Honoraria);